SCHEMBL5142947

SCHEMBL5142947

O=c1oc2cc(O)ccc2c(-c2ccccc2)c1-c1ccc(Br)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.74
ESR2 Q92731 3/20 0.74
ERAP1 Q9NZ08 1/20 0.65
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
POLB P06746 2/20 0.54
USP2 O75604 1/20 0.54
ATM Q13315 1/20 0.54
PLEC Q15149 1/20 0.54
NPSR1 Q6W5P4 1/20 0.52
RXFP1 Q9HBX9 1/20 0.52
MIF P14174 2/20 0.52
MAOA P21397 3/20 0.51
CA12 O43570 2/20 0.51
AKR1B1 P15121 2/20 0.51
MAOB P27338 2/20 0.51
HSD17B3 P37058 2/20 0.51
CA9 Q16790 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3366067 0.92 ESR1 (0.88) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL8934513 0.92 ESR1 (0.88) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL31675834 0.92 ESR1 (0.82) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL5082203 0.92 ESR1 (0.82) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL7165990 0.86 ESR1 (0.74) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL5084963 0.83 NPC1 (0.73) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL7113502 0.82 ERAP1 (0.75) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL11478035 0.81 ERAP1 (0.74) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL13183988 0.81 ESR1 (0.77) ESR1ESR2ERAP1KDM4EALDH1A1
SCHEMBL7155199 0.81 ALDH1A1 (0.58) KDM4EALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007115181-A9 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEM CO (US) 2008-04-03 WO disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 ESR1 258/4885ESR2 145/4885ERAP1 2734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.